Seeking Alpha

Karyopharm presents Selinexor data at ASH

  • Karyopharm Therapeutics' (KPTI) Selinexor "showed preliminary evidence of anti-cancer activity as a single agent" in most relapsed/refractory NHL and CLL patients from a cohort comprised of those with progressive disease on entry.
  • Data summary from the Phase 1 trial in advanced hematologic malignancies: PRs, 27%; SD, 50%; tumor shrinkage in 17 of 18 patients. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: